Article

European specialist shares perspectives on glaucoma surgery

When it comes to questions about the timing of glaucoma surgery and procedure choice, the general consensus in Europe is that early is better than late. According to guidelines from the European Glaucoma Society (EGS), nonpenetrating glaucoma surgery (NPGS) is a viable alternative to trabeculectomy, said Tarek Shaarawy, MD.

When it comes to questions about the timing of glaucoma surgery and procedure choice, the general consensus in Europe is that early is better than late. According to guidelines from the European Glaucoma Society (EGS), nonpenetrating glaucoma surgery (NPGS) is a viable alternative to trabeculectomy, said Tarek Shaarawy, MD.

Support for early surgical intervention finds its roots in pioneering work at Moorfields Eye Hospital, London, from glaucoma surgeons who showed that surgery was more effective than medical therapy in achieving visual field stability and IOP reduction, he said.

"These findings have since been corroborated by other multicenter studies," said Dr. Shaarawy, head, glaucoma sector, ophthalmology service, Department of Clinical Neurosciences, University of Geneva, Switzerland.

Discussing procedure choice, he noted that a more favorable safety profile is the primary reason why NPGS achieved a place alongside trabeculectomy in the EGS Terminology and Guidelines.

"Even leaders in glaucoma who [believe] trabeculectomy offers better IOP reduction accept that NPGS has a better safety margin and is deserving of a fair chance," Dr. Shaarawy said.

In contrast to trabeculectomy, NPGS is almost devoid of significant hypotony and is associated with a significantly lower incidence of cataract, he explained. Furthermore, after more than 25 years of experience with deep sclerectomy around the world, this nonpenetrating procedure has not been associated with a single published report of endophthalmitis, according to Dr. Shaarawy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.